Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, et al. Retinoblastoma. Nat Rev Dis Prim. 2015;1:15021.

Article  PubMed  Google Scholar 

Xu XL, Singh HP, Wang L, Qi D-L, Poulos BK, Abramson DH, et al. Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature. 2014;514:385–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: a 2020 review. Indian J Ophthalmol. 2020;68:2356–65.

Article  PubMed  PubMed Central  Google Scholar 

Rodriguez-Galindo C, Chantada GL, Haik BG, Wilson MW. Treatment of retinoblastoma: current status and future perspectives. Curr Treat Options Neurol. 2007;9:294–307.

Article  PubMed  Google Scholar 

Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:48.

Article  PubMed  PubMed Central  Google Scholar 

Shapiro P, Martinez R, Defnet A. Introduction to kinases, cellular signaling, and kinase inhibitors. In: Shapiro P, editor. Next generation kinase inhibitors: moving beyond the ATP binding/catalytic sites. Cham: Springer International Publishing; 2020. p. 1-12.

Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. J Clin Invest. 2015;125:1780–9.

Article  PubMed  PubMed Central  Google Scholar 

Sawyers C. Targeted cancer therapy. Nature. 2004;432:294–7.

Article  CAS  PubMed  Google Scholar 

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP. et al. Long-term outcomes imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update. Pharmacol Res. 2023;187:106552.

Article  CAS  PubMed  Google Scholar 

Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820–3.

Article  PubMed  PubMed Central  Google Scholar 

Benavente CA, Dyer MA. Genetics and epigenetics of human retinoblastoma. Annu Rev Pathol. 2015;10:547–62.

Article  CAS  PubMed  Google Scholar 

Laurie N, Shih CS, Dyer MA. Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets. 2007;7:689–95.

Article  CAS  PubMed  Google Scholar 

Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature. 2012;481:329–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sujjitjoon J, Sayour E, Tsao ST, Uiprasertkul M, Sanpakit K, Buaboonnam J, et al. GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction. Transl Oncol. 2021;14:100971.

Article  CAS  PubMed  Google Scholar 

Schaiquevich P, Francis JH, Cancela MB, Carcaboso AM, Chantada GL, Abramson DH. Treatment of retinoblastoma: what is the latest and what is the future. Front Oncol. 2022;12:822330

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic acids Res. 1988;16:1215.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Devarajan B, Prakash L, Kannan TR, Abraham AA, Kim U, Muthukkaruppan V, et al. Targeted next generation sequencing of RB1 gene for the molecular diagnosis of retinoblastoma. BMC Cancer. 2015;15:320.

Article  PubMed  PubMed Central  Google Scholar 

Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 2015;24:2125–37.

Article  CAS  PubMed  Google Scholar 

Laskowski RA, Stephenson JD, Sillitoe I, Orengo CA, Thornton JM. VarSite: disease variants and protein structure. Protein Sci. 2020;29:111–19.

Article  CAS  PubMed  Google Scholar 

Webb B, Sali A. Comparative protein structure modeling using MODELLER. Curr Protoc Bioinform. 2016;54:5.6.1–5.6.37.

Article  Google Scholar 

Rodrigues CH, Pires DE, Ascher DB. DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability. Nucleic acids Res. 2018;46:W350–W55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lonigro RJ, Grasso CS, Robinson DR, Jing X, Wu YM, Cao X, et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia. 2011;13:1019–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira C, Wolf T. CNVPanelizer: reliable CNV detection in targeted sequencing applications. R package version 1.18.0. 2019. https://bioconductor.org/packages/release/bioc/html/CNVPanelizer.html.

Balaji S, Santhi R, Kim U, Muthukkaruppan V, Priya CG, Vanniarajan A. Cancer stem cells with overexpression of neuronal markers enhance chemoresistance and invasion in retinoblastoma. Curr Cancer Drug Targets. 2020;20:710–19.

Article  CAS  PubMed  Google Scholar 

Kooi IE, Mol BM, Massink MP, Ameziane N, Meijers-Heijboer H, Dommering CJ, et al. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. Sci Rep. 2016;6:25264.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Afshar AR, Pekmezci M, Bloomer MM, Cadenas NJ, Stevers M, Banerjee A, et al. Next-generation sequencing of retinoblastoma identifies pathogenic alterations beyond RB1 inactivation that correlate with aggressive histopathologic features. Ophthalmology. 2020;127:804–13.

Article  PubMed  Google Scholar 

Francis JH, Richards AL, Mandelker DL, Berger MF, Walsh MF, Dunkel IJ, et al. Molecular changes in retinoblastoma beyond RB1: findings from next-generation sequencing. Cancers. 2021;13:149.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mendonça V, Evangelista AC, Matta BP, Moreira MÂM, Faria P, Lucena E, et al. Molecular alterations in retinoblastoma beyond RB1. Exp Eye Res. 2021;211:108753.

Article  PubMed  Google Scholar 

Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17:58.

Article  PubMed  PubMed Central  Google Scholar 

Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, et al. Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med. 2012;4:675–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bowles E, Corson TW, Bayani J, Squire JA, Wong N, Lai PB, et al. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosom Cancer. 2007;46:118–29.

Article  CAS  PubMed